Diagnosis and treatment algorithm

A standardized algorithm for the diagnosis and treatment of male hypogonadism is summarized in the Figure 1.1
Hypogonadism - Diagnosis & Treatment Algorithm
vergrößern Figure 11: Practical algorithm for work-up and management of testosterone deficiency

Practical Algorithm for work-up and management of testosterone-deficiency

Although definite evidence is lacking about the impact of testosterone therapy on metabolic endpoints, an international group of authors  presents here an innovative approach based on supportive data regarding surrogate endpoints or early-term results. The authors believe existing data indicate that a diagnostic work-up is warranted in all of these men.

  1. Total testosterone (T) has been the traditional method to diagnose testosterone deficiency. A number of suggested thresholds have been published. (61,105) However, T assays produce highly variable results and treatment must be individualized based on a combination of clinical presentation and biochemical results. Genetic variation may lead to symptoms of T deficiency in men with normal total T results.
  2. Free T can be of diagnostic help in cases where total T does not correspond with clinical presentation. Clinical use of free T is complicated by the availability of a number of assays, and a lack of consensus regarding threshold values. We suggest 8ng/dL (270pmol/L) for calculated free T. The analog free T assay (111,112) shows good correlation with calculated free T, corresponds with biological outcomes, and in our experience has clinical utility, albeit controversial. Values <1,5ng/dL (52 pmol/L) obtained by the analog free T assay have been suggested as indicating the lower limit of normal.
  3. Men with a suspicions prostate examination, or elevated prostate-specific antigen (PSA) should be referred to a urologist for consideration of prostate biopsy before initiation of T therapy. The use of T therapy in men with a prior history of prostate cancer has historically been an absolute contraindication to T therapy. This is an area of active investigation, with recent evidence suggesting the risk is considerably lower than once believed. However we recommend that the non-specialist refrain from initiating treatment in such men until there is clearer information as to which men with prior history of prostate cancer may be safely offered T therapy. Contraindications include the presence of elevated hemoglobin or hematocrit at baseline and the desire to initiate a pregnancy within the next 12 months.
  4. A symptomatic response to T therapy is generally seen within 3 months. Monitoring should occur at least 2-3times during the first year, and 1-2 times per year thereafter. Monitoring should include serum T,PSA levels, and hematocrit/hemoglobin. There is no need to measure liver or renal function tests for any of the routine T-therapy formulations.
  5. Severe reductions in total T, (ie. <250ng(dL [8 nmol/L] are usually accompanied by symptoms or objective measures of T deficiency. Additional diagnostic studies may be indicated depending on the clinical presentation, for example, to exclude the presence of pituitary mass or genetic tests.
  6. In cases of pituitary disease, genetic causes, unstable glucose control, testicular abnormalities, or the wish for paternity, a specialist should cooperate with the treating physician. PDE-5 =phosphodiesterase type-5

References

1 Traish A et al., Testosterone Deficiency, The American J of Medicine (2011) 124:578-587.

Last updated: 2018
G.MKT.GM.MH.01.2018.0500